Table 1. Description of the overall... | American Society of Hematology

Table 1.

Description of the overall population at the time of study

Patient characteristics	Stage II, n = 6	Stage III, n = 25	All patients,^* n = 31
Median age, y (range)	49.5(46-73)	62.0(43-84)	61.0(43-84)
Male:female	1:5	5:20	6:25
Median M protein, mg/dL (range)†	800(150-1700)	1200(158-6000)	1200(150-6000)
Median β₂-microglobulin, mg/L (range)	1.86(0.96-3.5)	2.47(1.02-12)	2.26(0.96-12)
Treatment with thalidomide, n
Untreated	3	5	8
≤2 weeks	0	5	5
> 2 weeks and < 4 months	0	4	4
≥4 months	3	11	14
Median percent CECs
All patients (range)	0.87(0.58-1.49)	0.64(0.13-2.04)	0.73(0.13-2.04)
Healthy controls (range)	NA	NA	0.05(0.1-0.66)

Patient characteristics	Stage II, n = 6	Stage III, n = 25	All patients,^* n = 31
Median age, y (range)	49.5(46-73)	62.0(43-84)	61.0(43-84)
Male:female	1:5	5:20	6:25
Median M protein, mg/dL (range)†	800(150-1700)	1200(158-6000)	1200(150-6000)
Median β₂-microglobulin, mg/L (range)	1.86(0.96-3.5)	2.47(1.02-12)	2.26(0.96-12)
Treatment with thalidomide, n
Untreated	3	5	8
≤2 weeks	0	5	5
> 2 weeks and < 4 months	0	4	4
≥4 months	3	11	14
Median percent CECs
All patients (range)	0.87(0.58-1.49)	0.64(0.13-2.04)	0.73(0.13-2.04)
Healthy controls (range)	NA	NA	0.05(0.1-0.66)

Staging was done at diagnosis in accordance with Jacobsen et al.⁴²

NA indicates not applicable to healthy controls.

Not all patients underwent all of the studies described in the “Results” section.

In 2 cases of light chain MM, Bence-Jones protein was considered as M protein.